Posted in Clinical Data Data backs GSK’s ovarian cancer blockbuster hopes April 13, 2026 Pharmaphorum GSK’s B7-H4-targeting ADC Mo-Rez chalks up impressive results in ovarian and endometrial cancer, prompting a major phase 3 trials programme. Clinical DataOncologyRead full story